Nattokinase vs Serrapeptase
A side-by-side research comparison of Nattokinase and Serrapeptase across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Nattokinase | Serrapeptase |
|---|---|---|
| Full name | Nattokinase (Subtilisin NAT) | Serrapeptase (Serratiopeptidase) |
| Category | Cardiovascular | Cardiovascular |
| Status | Dietary supplement | Dietary supplement |
| Mechanism | Directly degrades fibrin in blood clots via proteolytic activity. Also activates endogenous tissue plasminogen activator (tPA) and suppresses plasminogen activator inhibitor-1 (PAI-1), enhancing the body's own fibrinolytic system. | Degrades non-living tissue including fibrin, blood clots, mucus, and arterial plaque without harming living cells. Inhibits bradykinin release and reduces prostaglandin synthesis for anti-inflammatory effects. |
| Molecular weight | ~27,728 Da | ~52,000 Da |
| Half-life | ~8-12 hours (fibrinolytic activity) | ~4-6 hours |
| Bioavailability | Oral absorption confirmed; survives GI tract | Oral (enteric-coated required); detectable in bloodstream |
| Typical dose | 2000-4000 FU (fibrinolytic units) | 120,000-240,000 SPU |
| Frequency | Daily on empty stomach | Daily on empty stomach |
| Route | Oral capsule | Oral (enteric-coated) |
Nattokinase reported benefits
- Fibrin clot dissolution
- Blood pressure reduction
- Improved blood viscosity
- Reduced DVT risk
- Atherosclerosis prevention
- Natural anticoagulant alternative
Serrapeptase reported benefits
- Reduced inflammation and swelling
- Arterial plaque modulation
- Mucus/biofilm breakdown
- Post-surgical recovery
- Sinus/respiratory clearing
- Pain reduction
Related comparisons
Research and educational reference only. Not medical advice.